1 / 8

Pediatric Growth Hormone Deficiency

The Pediatric Growth Hormone Deficiency (PGHD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Pediatric Growth Hormone Deficiency (PGHD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. <br><br>

yashb
Download Presentation

Pediatric Growth Hormone Deficiency

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatric Growth Hormone Deficiency: Symptoms and Treatment in 2021 By- DelveInsight Business Research

  2. Pediatric Growth Hormone Deficiency Market To diagnose the GHD, the healthcare providers check for conditions such as normal variations of growth, such as short familial stature; other disorders, such as thyroid hormone deficiency or kidney disease, and genetic conditions, can be identified using blood tests, X-ray, CT Scan, and MRI.

  3. Treatment is mainly done with daily injections of synthetic growth hormone, and the results are often seen just after 3-4 months of starting the treatment regimen. The treatment can last several years until late puberty when growing is finished. GHD affects males and females equally, except for GHD III (Idiopathic GHD) which affects only males.

  4. However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. The organization also quoted that about 73% of patients with idiopathic GHD in the National Cooperative Growth Study were males. 

  5. Additionally, patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male. “Growth Hormone Research Society perspective on biomarkers of GH action in children and adults,” which stated that in paediatricpatients

  6. There is currently an unmet need for better predictors of GH treatment efficacy in relation to linear growth response, metabolic benefit and safety.  There is also a need for biomarkers that reflect therapeutic response in specific tissues such as the growth plate and skeleton in a variety of disorders associated with short stature. Read More @ Pediatric Growth Hormone Deficiency Market Report

  7. Thank you

More Related